News & Updates
Filter by Specialty:

PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib
The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.
PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib
15 Jan 2023
KRAS G12C inhibitors show promise in metastatic colorectal and pancreatic cancers
The KRASG12C inhibitors, adagrasib and sotorasib, have shown promising antitumour activity in patients with heavily pretreated metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer, respectively.
KRAS G12C inhibitors show promise in metastatic colorectal and pancreatic cancers
13 Jan 2023
Recent hyperglycaemia helps detect pancreatic cancer early
Pancreatic cancer may be identified early if assessment will be steered towards the point of recent hyperglycaemia based on elevated HbA1c, suggests a retrospective cohort study, noting that such early detection may then improve survival in cancer patients.
Recent hyperglycaemia helps detect pancreatic cancer early
11 Jan 2023
Meta-analysis: No link between PPI use and gastric cancer
Proton pump inhibitor (PPI) therapy does not appear to put individuals who require gastric acid suppression at increased risk of gastric cancer, according to a study.
Meta-analysis: No link between PPI use and gastric cancer
11 Jan 2023
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
08 Jan 2023
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.